Profile of NOPR Cohort
| Lung | Prostate | Other | ||||
| Patient profile, indication, and findings | IS | FOM | IS | FOM | IS | FOM |
| Number | 216 | 362 | 2,701 | 4,749 | 496 | 1,374 |
| Age, median 25%–75% quartile (y) | 73 (68–77) | 74 (69–80) | 73 (69–78) | 76 (71–82) | 75 (69–81) | 75 (70–80) |
| Symptoms, signs, or test results (%) | ||||||
| None | 70 (32.4) | 43 (11.9) | 1,574 (58.3) | 732 (15.4) | 231 (46.6) | 142 (10.3) |
| Elevated or rising tumor marker or PSA only | * | * | 724 (26.8) | 2,368 (49.9) | * | 77 (5.6) |
| Pain only | 80 (37.0) | 213 (58.8) | 142 (5.3) | 683 (14.4) | 165 (33.3) | 733 (53.3) |
| Evidence from other imaging | 28 (13.0) | 40 (11.0) | 117 (4.3) | 293 (6.2) | 49 (9.9) | 145 (10.6) |
| Multiple | 20 (9.3) | 43 (11.9) | 98 (3.6) | 550 (11.6) | 24 (4.8) | 197 (14.3) |
| NaF PET findings (%) | ||||||
| Benign or equivocal | 139 (64.4) | 216 (59.7) | 2,198 (81.4) | 2,886 (60.8) | 391 (78.8) | 934 (68.0) |
| Probable metastases | 17 (7.9) | 34 (9.4) | 164 (6.1) | 439 (9.2) | 29 (5.8) | 108 (7.9) |
| Definite bone metastases | ||||||
| Unifocal | 12 (5.6) | 18 (5.0) | 36 (1.3) | 163 (3.4) | 13 (2.6) | 46 (3.3) |
| Multifocal | 41 (19.0) | 80 (22.1) | 227 (8.4) | 951 (20.0) | 47 (9.5) | 206 (15.0) |
| Diffuse | * | 14 (3.9) | 76 (2.8) | 310 (6.5) | 16 (3.2) | 80 (5.8) |
| Stage, post–NaF PET (%) | ||||||
| Local/NED | 60 (27.8) | 168 (46.4) | 1,974 (73.1) | 1,794 (37.8) | 288 (58.1) | 792 (57.6) |
| LN+/regional | 33 (15.3) | 10 (2.8) | 81 (3.0) | 739 (15.6) | 29 (5.8) | 49 (3.6) |
| Single metastases | 24 (11.1) | 39 (10.8) | 134 (5.0) | 553 (11.6) | 40 (8.1) | 123 (9) |
| Multiple metastases | 91 (42.1) | 145 (40.1) | 393 (14.6) | 1,663 (35.0) | 111 (22.4) | 410 (29.8) |
| Unknown | * | * | 119 (4.4) | * | 28 (5.6) | * |
| Characteristics from claims | ||||||
| Hospitalized within 180 d after NaF PET (%) | 117 (54.2) | 157 (43.3) | 542 (20.0) | 820 (17.2) | 187 (37.7) | 349 (25.4) |
| Hospice within 60 d after NaF PET (%) | 17 (7.9) | 42 (11.6) | * | 60 (1.2) | 13 (2.6) | 54 (3.9) |
| Death within 180 d after NaF PET (%) | 68 (31.5) | 128 (35.3) | 47 (1.7) | 249 (5.2) | 64 (12.9) | 168 (12.2) |
| Medicare Part D claims found (%) | 151 (69.9) | 223 (61.6) | 1,503 (55.6) | 2,668 (56.1) | 303 (61.0) | 848 (61.7) |
↵* Cell count < 11.
PSA = prostate-specific antigen; NED= no evidence of disease; LN+ = lymph nodal disease positive.
Data in parentheses are percentages.